Post by account_disabled on Dec 26, 2023 1:48:05 GMT -5
Executive Vice President, Research and Development AstraZeneca Biopharmaceuticals said : “The findings published in further support for the use of Evusheld to help patients who need it. Need protection against COVID -19 disease more than the general public At this time there has been discussion regarding About the information from this study to relevant agencies and has been submitted for consideration Drug registration for all indications We are continuously working on treatment and prevention to fight COVID-19 in every aspect.”
The primary endpoint of the TACKLE trial Phone Number Data was that one 600 mg intramuscular dose of Evusheld reduced the risk of severe disease . or death (from all causes) up to 50% ( 95 % confidence interval ( CI) 15, 71; p=0.010 ) after receiving the drug for 29 days compared to the group receiving placebo ( Placebo) in Outpatients with mild to moderate symptoms and have had symptoms for no more than 7 days From the analysis pre-specified In symptomatic COVID- 19 patients who received the drug within the first three days,
Evusheld was found to reduce the risk of severe disease or death. (from any cause) up to 88% compared to the group receiving placebo ( Placebo) (95% confidence interval ( CI) 9, 9 8 ) and also reduced the risk by 67% (95% confidence interval (CI) 9, 9 8 ) and also reduced the risk by 67% (95% confidence interval (CI) Confidence ( CI) 31, 84 ) in the group that received medication within 5 days after symptoms appeared 1 In addition, in the secondary endpoint reported.
The primary endpoint of the TACKLE trial Phone Number Data was that one 600 mg intramuscular dose of Evusheld reduced the risk of severe disease . or death (from all causes) up to 50% ( 95 % confidence interval ( CI) 15, 71; p=0.010 ) after receiving the drug for 29 days compared to the group receiving placebo ( Placebo) in Outpatients with mild to moderate symptoms and have had symptoms for no more than 7 days From the analysis pre-specified In symptomatic COVID- 19 patients who received the drug within the first three days,
Evusheld was found to reduce the risk of severe disease or death. (from any cause) up to 88% compared to the group receiving placebo ( Placebo) (95% confidence interval ( CI) 9, 9 8 ) and also reduced the risk by 67% (95% confidence interval (CI) 9, 9 8 ) and also reduced the risk by 67% (95% confidence interval (CI) Confidence ( CI) 31, 84 ) in the group that received medication within 5 days after symptoms appeared 1 In addition, in the secondary endpoint reported.